(Angiosarcoma) Is Carotuximab Plus Pazopanib Effective?

• April 18, 2022
• Reading time: 1 minute

On March 31, 2022, Robin L. Jones et al. from Royal Marsden Hospital and Institute of Cancer Research published in JAMA Oncology the efficacy and safety results of the anti-CD105 antibody carotuximab plus the multikinase inhibitor pazopanib in advanced angiosarcoma from the TAPPAS Phase 3 trial.

Trial Design

This was an international, multicenter, randomized Phase 3 trial enrolling advanced angiosarcoma patients (N=123), randomized to:

• Carotuximab group: Carotuximab 10 mg/kg once weekly + pazopanib 800 mg once daily
• Pazopanib group: Pazopanib 800 mg once daily

Treatment continued until disease progression or unacceptable toxicity. Primary endpoint: PFS. Secondary endpoints: ORR, OS.

Patient characteristics (114 evaluable patients — pazopanib N=53, carotuximab N=61):

• Female: 61% (N=69)
• Median age: 68 years (range 24–82)

Efficacy Results

Median PFS (primary endpoint):

• Pazopanib group: 4.3 months
• Carotuximab group: 4.2 months — No significant difference between the two arms.

Safety Profile

Most common adverse events (Pazopanib vs. Carotuximab):

• Fatigue: 55% / 61%
• Headache: 23% / 64%
• Diarrhea: 51% / 57%
• Nausea: 49% / 48%
• Vomiting: 23% / 38%
• Anemia: 9% / 44%
• Epistaxis: 4% / 56%
• Hypertension: 55% / 36%

Conclusions

Based on the TAPPAS trial results, Robin L. Jones et al. concluded that carotuximab plus pazopanib did not significantly improve PFS compared to pazopanib monotherapy in advanced angiosarcoma patients.

Source: https://jamanetwork.com/journals/jamaoncology/fullarticle/2790727

• Clinical trial drug

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4